Free Trial
→ A new rule goes live in July — and the banks are quietly cashing in (From American Alternative) (Ad)
NASDAQ:XBIT

XBiotech 11/9/2023 Earnings Report

XBiotech logo
$2.58 +0.08 (+3.32%)
As of 02:11 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
ProfileEarnings History

XBiotech EPS Results

Actual EPS
-$0.24
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

XBiotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

XBiotech Announcement Details

Quarter
Date
11/9/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

XBiotech's next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules.

Conference Call Resources

XBiotech Earnings Headlines

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
February 4, 2025 | prnewswire.com
XBiotech stock hits 52-week low at $3.5 amid market challenges
January 28, 2025 | msn.com
The Private Market Surge Is Coming in 2025
The most lucrative investment opportunities are reserved for a select category of investor. They're private. They're quiet. And they're often available exclusively to accredited investors operating outside the noise of the public markets. We're talking about off-market placements, early venture deals, private credit, and pre-IPO shares—the kind of plays that can generate outsized gains before Wall Street catches wind. Here's the reality: having access is only the beginning. These deals can be opaque, rushed, and filled with hidden risk. That's why we created something exclusively for investors like you—the 2025 Accredited Investor Playbook.
June 23, 2025 | Darwin (Ad)
XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm
January 17, 2025 | prnewswire.com
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws
January 14, 2025 | globenewswire.com
XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm
January 13, 2025 | businesswire.com
See More XBiotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XBiotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XBiotech and other key companies, straight to your email.

About XBiotech

XBiotech (NASDAQ:XBIT), a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

View XBiotech Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles